

APC/Cyanine7 anti-mouse CD4 Antibody

Catalog# / Size	100525 / 25 µg 100526 / 100 µg
Clone	RM4-5
Regulatory Status	RUO
Other Names	L3T4, T4
Isotype	Rat IgG2a, κ
Description	CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	BALB/c mouse thymocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4 ⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, <i>in vivo</i> depletion of CD4 ⁺ cells ¹ , and immunohistochemistry of acetone-fixed frozen tissue sections ^{2,3,11} and paraffin-embedded sections ¹¹ . Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).
Additional Product Notes	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References	<ol style="list-style-type: none"> 1. Kruisbeek AM. 1991. <i>In Curr. Protocols Immunol.</i> pp. 4.1.1-4.1.5. (Block, Deplete) 2. Nitta H, <i>et al.</i> 1997. <i>Cell Vision</i> 4:73. (IHC) 3. Fan WY, <i>et al.</i> 2001. <i>Exp. Biol. Med.</i> 226:1045. 4. Muraille E, <i>et al.</i> 2003. <i>Infect. Immun.</i> 71:2704. (IHC) 5. León-Ponte M, <i>et al.</i> 2007. <i>Blood</i> 109:3139. (FC) 6. Bourdeau A, <i>et al.</i> 2007. <i>Blood</i> doi:10.1182/blood-2006-08-044370. (FC) 7. Matsumoto M, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:2499. PubMed
(PubMed link indicates BioLegend citation)	

8. Shigeta A, *et al.* 2008. *Blood* 112:4915. [PubMed](#)
9. Zaborsky N, *et al.* 2010. *J. Immunol.* 184:725. [PubMed](#)
10. Rodrigues-Manzanet R, *et al.* 2010. *P. Natl Acad Sci USA* 107:8706. [PubMed](#)
11. Whiteland JL, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)

Product Citations

1. Jarick KJ, *et al.* 2018. *Front Immunol.* 9:1468. [PubMed](#)
2. Xiong W, *et al.* 2022. *Nat Commun.* 13:1700. [PubMed](#)
3. Koh CH, *et al.* 2020. *Cancer Immunol Res.* 8:698. [PubMed](#)
4. Ma F, *et al.* 2020. *Cell Death Dis.* 1.17222222. [PubMed](#)
5. Turner JS *et al.* 2018. *Cell reports.* 25(6):1395-1403. [PubMed](#)
6. Acharya N, *et al.* 2020. *Immunity.* 53(3):658-671.e6. [PubMed](#)
7. Tordesillas L, *et al.* 2018. *Nat Commun.* 9:5238. [PubMed](#)
8. Pokrovskii M, *et al.* 2020. *EMBO J.* 39:e104159. [PubMed](#)
9. Pan H, *et al.* 2020. *Mol Psychiatry.* [PubMed](#)
10. Bartleson JM, *et al.* 2020. *Nat Immunol.* 1384:21. [PubMed](#)
11. Ogawa C *et al.* 2018. *Cell reports.* 25(1):19-28. [PubMed](#)
12. Yang W, *et al.* 2020. *Mucosal Immunol.* 13:788. [PubMed](#)
13. Peng L, *et al.* 2020. *Transl Lung Cancer Res.* 0.892361111. [PubMed](#)
14. Guo HF, *et al.* 2021. *Commun Biol.* 4:482. [PubMed](#)
15. Wei M, *et al.* 2014. *Protein Eng Des Sel.* 27:289. [PubMed](#)
16. Len-Letelier RA, *et al.* 2020. *Frontiers in Immunology.* 11:583382. [PubMed](#)
17. Shiomi A, *et al.* 2014. *J Immunol.* 193:849. [PubMed](#)
18. Cuburu N, *et al.* 2019. *J Immunol.* 202:1250. [PubMed](#)
19. Westfall S, *et al.* 2020. *Brain Behav Immun.* [PubMed](#)
20. Mencarelli A, *et al.* 2016. *Sci Rep.* 6:30802. [PubMed](#)
21. Dietmar Herndler-Brandstetter *et al.* 2018. *Immunity.* 48(4):716-729. [PubMed](#)
22. Synn CB, *et al.* 2022. *Clin Transl Immunology.* 11:e1364. [PubMed](#)
23. Taniguchi H, *et al.* 2022. *Cell Rep.* 39:110814. [PubMed](#)
24. Witkowski MT, *et al.* 2020. *Cancer Cell.* 37:867. [PubMed](#)
25. Ringel AE, *et al.* 2020. *Cell.* 183(7):1848-1866.e26. [PubMed](#)
26. Mender I, *et al.* 2020. *Cancer Cell.* 38(3):400-411.e6. [PubMed](#)
27. Bankoti R, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-12171-3. [PubMed](#)
28. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
29. Tan X, *et al.* 2021. *Sci Adv.* 7: [PubMed](#)
30. Denny JE, *et al.* 2019. *Sci Rep.* 2.786111111. [PubMed](#)
31. Kubota S, *et al.* 2019. *Nat Commun.* 10:1653. [PubMed](#)
32. Biton M *et al.* 2018. *Cell.* 175(5):1307-1320. [PubMed](#)
33. De Ponte Conti B, *et al.* 2021. *Elife.* 10: [PubMed](#)
34. Melo-Silva CR, *et al.* 2021. *PLOS Pathogens.* 17(5):e1009593. [PubMed](#)
35. Saigusa R, *et al.* 2018. *Arthritis Res Ther.* 20:23. [PubMed](#)
36. Boehm DT, *et al.* 2019. *NPJ Vaccines.* 4:40. [PubMed](#)
37. Lou Y, *et al.* 2021. *Int J Mol Sci.* 22: [PubMed](#)
38. Dionisio-Santos DA, *et al.* 2021. *Front Neurosci.* 15:758677. [PubMed](#)
39. Chen RJ, *et al.* 2022. *iScience.* 25:105595. [PubMed](#)
40. Gladow N, *et al.* 2020. *PLoS One.* 15:e0227734. [PubMed](#)
41. Clement CC, *et al.* 2021. *Immunity.* 54:721. [PubMed](#)
42. Brenndörfer E, *et al.* 2014. *J Immunol.* 192:1671. [PubMed](#)
43. Yokomizo-Nakano T, *et al.* 2020. *Cancer Res.* 80:2523. [PubMed](#)
44. Yun H, *et al.* 2020. *Immunity.* 53(5):1050-1062.e5. [PubMed](#)
45. Ulrich V, *et al.* 2016. *EMBO Mol Med.* 8: 643 - 653. [PubMed](#)
46. Weng Q, *et al.* 2018. *Cell Regen (Lond).* 7:7. [PubMed](#)
47. Koide S, *et al.* 2022. *iScience.* 25:103603. [PubMed](#)
48. Ding L *et al.* 2018. *Cell reports.* 25(11):2972-2980. [PubMed](#)
49. Fitzpatrick Z, *et al.* 2020. *Nature.* 587:472. [PubMed](#)
50. Aryal B, *et al.* 2016. *Nat Commun.* 7:12313. [PubMed](#)
51. Ding Z, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-12488-z [PubMed](#)
52. Kumar R, *et al.* 2020. *Cell Reports.* 30(8):2512-2525. [PubMed](#)
53. Guo Y, *et al.* 2021. *Nat Immunol.* 22:746. [PubMed](#)
54. Gonzalez-Figueroa P, *et al.* 2021. *Cell.* 184(7):1775-1789.e19. [PubMed](#)
55. Howie D, *et al.* 2019. *Front Immunol.* 10:1860. [PubMed](#)
56. Cobbold SP, *et al.* 2018. *Front Immunol.* 9:1381. [PubMed](#)
57. Li X, *et al.* 2021. *Front Immunol.* 12:779560. [PubMed](#)

RRID

AB_312726 (BioLegend Cat. No. 100525)
 AB_312727 (BioLegend Cat. No. 100526)

Antigen Details

Structure	Ig superfamily, 55 kD
Distribution	Majority of thymocytes, T cell subset
Function	TCR co-receptor, T cell activation
Ligand/Receptor	MHC class II molecule

Cell Type	Dendritic cells, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Bierer BE, <i>et al.</i> 1989. <i>Annu. Rev. Immunol.</i> 7:579. 3. Janeway CA. 1992. <i>Annu. Rev. Immunol.</i> 10:645.
Gene ID	12504


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD4, Biotin anti-mouse CD4, FITC anti-mouse CD4, PE anti-mouse CD4, PE/Cyanine5 anti-mouse CD4, Purified anti-mouse CD4, PE/Cyanine7 anti-mouse CD4, APC/Cyanine7 anti-mouse CD4, Alexa Fluor® 647 anti-mouse CD4, Alexa Fluor® 488 anti-mouse CD4, Pacific Blue™ anti-mouse CD4, Alexa Fluor® 700 anti-mouse CD4, PerCP anti-mouse CD4, PerCP/Cyanine5.5 anti-mouse CD4, Brilliant Violet 421™ anti-mouse CD4, APC/Fire™ 750 anti-mouse CD4, Brilliant Violet 570™ anti-mouse CD4, Brilliant Violet 605™ anti-mouse CD4, Brilliant Violet 650™ anti-mouse CD4, Brilliant Violet 711™ anti-mouse CD4, Brilliant Violet 785™ anti-mouse CD4, Brilliant Violet 510™ anti-mouse CD4, Purified anti-mouse CD4 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD4, TotalSeq™-A0001 anti-mouse CD4, TotalSeq™-B0001 anti-mouse CD4, TotalSeq™-C0001 anti-mouse CD4, Ultra-LEAF™ Purified anti-mouse CD4, Spark Violet™ 423 anti-mouse CD4 (L3T4) Antibody

Product Data



C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) APC/Cyanine7 (filled histogram) or rat IgG2a, κ APC/Cyanine7 isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587